198 related articles for article (PubMed ID: 30334694)
1. Triple CFTR Modulator Therapy for Cystic Fibrosis.
Holguin F
N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
[No Abstract] [Full Text] [Related]
2. CFTR mutations and cystic fibrosis.
Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
[No Abstract] [Full Text] [Related]
3. Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation.
McGarry ME
N Engl J Med; 2020 Feb; 382(7):684. PubMed ID: 32053310
[No Abstract] [Full Text] [Related]
4. A little CFTR can change a lot: slowing cystic fibrosis progression.
Rowe SM
Lancet Respir Med; 2017 Feb; 5(2):86-87. PubMed ID: 28011036
[No Abstract] [Full Text] [Related]
5. CFTR Modulator Therapy for Cystic Fibrosis.
Grasemann H
N Engl J Med; 2017 Nov; 377(21):2085-2088. PubMed ID: 29099349
[No Abstract] [Full Text] [Related]
6. Entering the era of highly effective CFTR modulator therapy.
Zemanick ET; Accurso FJ
Lancet; 2019 Nov; 394(10212):1886-1888. PubMed ID: 31679947
[No Abstract] [Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
8. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
9. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
10. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
12. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
13. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
14. Suppressing 'nonsense' in cystic fibrosis.
Hinzpeter A; Sermet-Gaudelus I; Sheppard DN
J Physiol; 2020 Feb; 598(3):429-430. PubMed ID: 31869855
[No Abstract] [Full Text] [Related]
15. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
Antoniu SA
Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
19. Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery in adult patients with cystic fibrosis.
Tagliati C; Lanni G; Battista D; Pantano S; Ripani P
Clin Otolaryngol; 2024 Mar; 49(2):243-246. PubMed ID: 37933411
[No Abstract] [Full Text] [Related]
20. Expanding access to CFTR modulators for rare mutations: The utility of n-of-1 trials.
Magaret AS; Mayer-Hamblett N; VanDevanter D
J Cyst Fibros; 2020 Jan; 19(1):1-2. PubMed ID: 31831338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
